Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed. It does not appear that there are many sellers out there.
Interesting mention of Axis in New York Times "Green Inc." Blog post yesterday:
July 29, 2009
4:25 pm
Just lighting efficiency contributes substantially to the energy savings. LED’s for security lighting. Automatic dimming ballasts for fluorescent lighting (depending upon light coming through windows and skylights). CFL instead of incandescent.
There are more and more companies seeing the opportunities. CREE Research has been relentless in introducing new LED applications. Axis Technologies - http://www.axistechnologyinc.com — have utilities offering rebates to their commercial clients that install their dimmable ballasts –which are an important tool to manage peak load demand.
But the key is converting talk and intent into action–and investment.
— Dave
TONE ($2.22) - what a chart of late! Looks to have bottomed and momentum is hard on the upside on higher than normal volume. Still trading well below book value of $14.46, and unfortunate foray into Florida and Las Vegas real estate loans now well in the past (sold or written off in prior quarters). This chart and story looks very interesting right now.
TONE ($2.22) Hard upward momentum continues today on good volume, and still trading well below book value of $14.46.
TONE ($2.20) Hard upward momentum continues today on higher volume, and still trading well below book value of $14.46.
TONE ($2.20) hard upward momentum continues today on excellent volume, and still trading well below book value of $14.46.
TONE ($2.20) - Upward momentum continues on excellent volume today, and still trading well below book value of $14.46.
TONE($2.20) Upward momentum continues on excellent volume, and still trading well below book value of $14.46.
TONE($2.20) Upward momentum continues on excellent volume, and still trading well below book value of $14.46.
TONE($2.20)-Upward momentum continues on higher volume, and still trading well below book value of $14.46.
TONE - looks to have bottomed and is running up hard on good volume. This bank has put Florida and Las Vegas real estate woes behind it in previous quarters, and is still trading well below book value. Worth a look, as brighter days are ahead.
TONE has bottomed and is running up hard on high volume. Hidden banking gem trading well below book value. Previous forays into Florida and Las Vegas real estate in rear view mirror (FL assets sold and Las Vegas written off in previous quarters), and bright days ahead.
TONE - Bank holding Co. looks to have bottomed and running up hard on higher than normal volume. Still trading way below book value. Hidden gem.
TONE - undervlaued bank hldg. Co. looks to have bottomed and is runing up hard on higher than normal volume. Still trading at less than 1/3 of book value.
TONE - undervalued bank loooks to have bottomed and is running up hard on higher than normal volume. Still trading well below book value.
TONE (undervalued Banking Co.) looks to have bottomed and is running up hard on higher than normal volume. Still traiding well below book value.
I see more positive than negative in the Q2 earnings report, but did not get to listen in on the conference call. I agree that the next months and year should be very interesting and potentially profitable for investors. Patience is a virtue.
I do not disagree with you. I have always been long on this thing in a big way. I was respondeng to Southern Gal's comment. She wants to be negative soooo bad some times.
You are calm compared to the past weeks and months. And, I appreciated your insight into the Hanson planned transfer/sale. I have not been concerned with the UL approval, and believe it will come in the near future. But what do I know.
Q2 earnnigs report and conference call is tomorrow. This should provide some interesting insight into where things are right now, although FDA approval of Zenvia is still the linchpin here.
Now that we have TRIXXX and Southern Gal calmed down, I think we can hopefully settle in for some positive times ahead for AXTG. I get as frustrated as anyone else, but believe the pieces will fall into place at some point in the near future for some positive growth and developments here.
That is good to know. Sounds more like a transfer of stock rather than a sale. People get all worked up over "insider sales." Insiders sell and/or transfer for a variety of reasons, e.g. to diversify investments, exercise an option, etc. In Gruenewald's case, it appears he may have had to seel, but heck, he sold less than 50,000 shares total in 2009 ...less than $12,000. A dro pin the busket, and of little to no significance.
Your insider sales topic is a red herring. Obviously there is no mass dumping of the stock today, as you advocated and predicted. And, no insider is going to sell the stock at this price with the looming prospects for the company over the coming weeks and months. Today's trade is telling. Only 100 shares at the weany opening market maker bid of .14, with the bid now at .16 and the ask at .19. Market makers are clearly trying to manipulate the stock, as they do not make money off of holders like us. They make money off of volitility and trading.
Do you have some evidence or a link to some information that there is actually sort of insider lockup which expires tomorrow (7/25/09)? I checked with IR and the company, and they know nothing about this. It seems that if one person posts something on these boards, it becomes fact.
I have been out of the Country for past week, but like the recent action in the stock.
I have been out of the country the past week, and still catching up. Disappointing that the spike in volume and PPS did not carry over from last Friday's buying. I still believe good news is likely around the corner, but who knows when. Hopefully sooned rather than later, but patience is apparently a requirement here.
Increase in volume, all at the ask, is very positive, but nonetheless a bit of a concern that this volume banging away at the ask cannot nudge the price up at all.
Hard to tell. The last time AVNR had a big spike in volume at the close was the day before it went into the Russell 3000 Index. I am not aware of any reason this time, but it could be short covering. I just always wonder why volume spikes like that in the last few minutes, as you would think shorts might cover earlier on a day like today.
Check out the volume right before the close today.
AVNR up on news:
Posted by: stocksablaze Date: Tuesday, July 14, 2009 10:43:54 AM
In reply to: stocksablaze who wrote msg# 1160 Post # of 1162
"Teva Pharmaceutical Industries stock gained 0.8% on reports that it's considering the acquisition of rights to Zenvia, a chronic pain medication being developed by a company called Avanir Pharmaceuticals. Alternately, Teva might buy the whole company, lock, stock and barrel."
http://www.haaretz.com/hasen/spages/1100047.html
AVNR up on news:
Posted by: stocksablaze Date: Tuesday, July 14, 2009 10:43:54 AM
In reply to: stocksablaze who wrote msg# 1160 Post # of 1162
"Teva Pharmaceutical Industries stock gained 0.8% on reports that it's considering the acquisition of rights to Zenvia, a chronic pain medication being developed by a company called Avanir Pharmaceuticals. Alternately, Teva might buy the whole company, lock, stock and barrel."
http://www.haaretz.com/hasen/spages/1100047.html
AVNR up on news
Posted by: stocksablaze Date: Tuesday, July 14, 2009 10:43:54 AM
In reply to: stocksablaze who wrote msg# 1160 Post # of 1162
"Teva Pharmaceutical Industries stock gained 0.8% on reports that it's considering the acquisition of rights to Zenvia, a chronic pain medication being developed by a company called Avanir Pharmaceuticals. Alternately, Teva might buy the whole company, lock, stock and barrel."
http://www.haaretz.com/hasen/spages/1100047.html
AVNR up on news
Posted by: stocksablaze Date: Tuesday, July 14, 2009 10:43:54 AM
In reply to: stocksablaze who wrote msg# 1160 Post # of 1162
"Teva Pharmaceutical Industries stock gained 0.8% on reports that it's considering the acquisition of rights to Zenvia, a chronic pain medication being developed by a company called Avanir Pharmaceuticals. Alternately, Teva might buy the whole company, lock, stock and barrel."
http://www.haaretz.com/hasen/spages/1100047.html
Interesting, but of great concern with AVNR trading at this level. I could be wrong, but we may not want that to happen just yet, with the stock at only $2. Better for someone to look at this type of deal down the road, but we can't control that. I am confident that the Avanir Board will have enough of a sense of the long term value of Zenvia to not let it go for a song. Who knows? - Maybe Teva is thinking it is a bargain even up in double digits. Just some thoughts.
Note: With AVNR now in the Russell 2000 and 3000 indexes, it will likely trade more in line with the overall market. That can be good and bad. But, in the end, Zenvia will become the driving force and take it to new highs.
AVNR seems to have calmed down and settled into a more muted trade. Obviously, due to the news on add to Russell 2000/3000 Index fading. But latest news on the fulfillment of the latest trial, etc. also good news. Believe nothing but positive going forward, and PPS should follow along in time.
I have reviewed the latest inductry update, and do not view it as just a "teaser." I think many of the communications we receive from IR are intended to be industry updates to interested parties who have signed up to receive them. They are not always PR's. Although I am anxious to see something more concrete, I do not see anything negative in sending out information on developmennts within the industry that could have a potential impact on AXTG, to people who have signed up to receive these updates. P.S. Looking for bigger news soon.
TRIXXX: this was not the information I was referring to in my post of yesterday. I agree that this is just background information.
Absolutely, it is a good sign. But the frustrating part is the delay after the first successful trial when the drug was formerly known as Neurodex, and the request for new "safety" data, wihich generated the more recent trials, etc. Zenvia will get to market, likely sometime in 2010, and will be a blockbuster drug for AVNR, which should lead to huge profits.
I know quite a bit about this drug, and its potential, which is incredible. The biggest problem they have is that some in the studies want to stay on it, and can't until it is approved.